Preclinical pharmacokinetics and in vitro ADME properties of PAT-1102: a novel HDAC inhibitor for cancer therapy.

Doreswamy CM, Seekallu S, Venkataramaiah SB, Umesh MC, Devi CS

Open source

DOI
10.1007/s00432-025-06227-5
Published
2025 May 24
Container
Journal of cancer research and clinical oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s00432-025-06227-5,
  title = {Preclinical pharmacokinetics and in vitro ADME properties of PAT-1102: a novel HDAC inhibitor for cancer therapy.},
  author = {Doreswamy CM and Seekallu S and Venkataramaiah SB and Umesh MC and Devi CS},
  year = {2025},
  journal = {Journal of cancer research and clinical oncology},
  doi = {10.1007/s00432-025-06227-5},
  url = {https://doi.org/10.1007/s00432-025-06227-5}
}

RIS

TY  - JOUR
TI  - Preclinical pharmacokinetics and in vitro ADME properties of PAT-1102: a novel HDAC inhibitor for cancer therapy.
AU  - Doreswamy CM
AU  - Seekallu S
AU  - Venkataramaiah SB
AU  - Umesh MC
AU  - Devi CS
PY  - 2025
JO  - Journal of cancer research and clinical oncology
DO  - 10.1007/s00432-025-06227-5
UR  - https://doi.org/10.1007/s00432-025-06227-5
ER  - 

APA

CM, D., S, S., SB, V., MC, U., & CS, D. (2025). Preclinical pharmacokinetics and in vitro ADME properties of PAT-1102: a novel HDAC inhibitor for cancer therapy.. Journal of cancer research and clinical oncology. https://doi.org/10.1007/s00432-025-06227-5

Source records